Home » Stocks » CPRX

Catalyst Pharmaceuticals, Inc. (CPRX)

Stock Price: $3.53 USD 0.03 (0.86%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $3.55 +0.02 (0.57%) Mar 5, 6:20 PM
Market Cap 357.59M
Revenue (ttm) 118.18M
Net Income (ttm) 71.48M
Shares Out 103.54M
EPS (ttm) 0.67
PE Ratio 5.27
Forward PE 11.11
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $3.53
Previous Close $3.50
Change ($) 0.03
Change (%) 0.86%
Day's Open 3.52
Day's Range 3.27 - 3.56
Day's Volume 1,699,483
52-Week Range 2.55 - 5.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerci...

GlobeNewsWire - 1 week ago

CORAL GABLES, Fla., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...

InvestorPlace - 2 weeks ago

Penny stocks are low price for a reason. Most presume they're destined for bankruptcy.

Other stocks mentioned: ABEV, AUY, BBD, NWG, WTI
24/7 Wall Street - 1 month ago

Now that AMC, GameStop, American Airlines and Bed, Bath & Beyond have been pushed to wild levels, well above any sane valuation, the question is which companies will be the next to be “recomme...

Other stocks mentioned: TXMD
The Motley Fool - 1 month ago

Investors can start the new year off right by digging into these three small but fiery stocks.

Other stocks mentioned: OGI, VXRT
Zacks Investment Research - 1 month ago

Catalyst (CPRX) plans to expand its product portfolio beyond Firdapse.

GuruFocus - 1 month ago

Investors focused on assets with high returns may want to consider the following non-cyclical stocks, as their earnings yields (as calculated through Joel Greenblatt's method) are outperformin...

Other stocks mentioned: NRG, TSN
GlobeNewsWire - 1 month ago

CORAL GABLES, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...

Seeking Alpha - 2 months ago

Catalyst Pharma is a commercial-stage small biotech with a highly profitable orphan drug Firdapse for adult LEMS patients in the US market. Catalyst Pharma is trading at PE ratio of 5 and pric...

Seeking Alpha - 2 months ago

Three referenced quant rating categories (value, growth, and profitability) are significant considerations in selecting healthcare investments. The data underlying the value, growth, and profi...

Other stocks mentioned: CODX, QDEL
Zacks Investment Research - 2 months ago

Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Investopedia - 2 months ago

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Other stocks mentioned: BDSI, BMRN, INVA, NVAX, VRTX, VXRT, VYGR
Zacks Investment Research - 2 months ago

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 3 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

Zacks Investment Research - 3 months ago

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

- Firdapse® Third Quarter Net Revenues of $ 29. 2 Million

Zacks Investment Research - 4 months ago

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

InvestorPlace - 4 months ago

Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk. The post Despite Legal Drama, Catalyst Pharmaceutic...

GlobeNewsWire - 4 months ago

CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...

GuruFocus - 4 months ago

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBI...

Other stocks mentioned: PRDO, SBR, VNDA, XBIT
InvestorPlace - 4 months ago

Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.

GlobeNewsWire - 4 months ago

CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercia...

Seeking Alpha - 4 months ago

Catalyst Pharmaceuticals Has Potential To Push Higher If They Can Overcome Current Headwinds

GlobeNewsWire - 4 months ago

Issued Patent is the First Covering Firdapse® Issued Patent is the First Covering Firdapse®

GlobeNewsWire - 5 months ago

CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FD...

24/7 Wall Street - 5 months ago

Investors often get excited about small-cap biotech and emerging pharmaceutical stocks because the upside can be exponential if their drugs and treatments become a hit.

Zacks Investment Research - 5 months ago

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 5 months ago

Catalyst can't seem to catch a break in the clinic these days.

Zacks Investment Research - 5 months ago

Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of con...

GlobeNewsWire - 6 months ago

Notice of Application for Judicial Review Filed Today in the Federal Court of Canada Notice of Application for Judicial Review Filed Today in the Federal Court of Canada

GlobeNewsWire - 6 months ago

CORAL GABLES, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...

Seeking Alpha - 6 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2020 Results - Earnings Call Transcript

The Motley Fool - 6 months ago

Firdapse fails to hit the mark in the clinic yet again.

Zacks Investment Research - 6 months ago

Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.

GlobeNewsWire - 6 months ago

-The allowed claims are directed to methods of treating patients with a 3,4-DAP sensitive disease comprising administering 3,4-DAP or a salt thereof to slow acetylating patients having certain...

Zacks Investment Research - 6 months ago

Catalyst (CPRX) delivered earnings and revenue surprises of 12.50% and 2.20%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

- Firdapse® Second Quarter Net Revenues of $29.6 Million

Benzinga - 6 months ago

Catalyst Pharmaceuticals (NASDAQ: CPRX) announces its next round of earnings this Monday, August 10.

GlobeNewsWire - 6 months ago

CORAL GABLES, Fla., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...

GlobeNewsWire - 7 months ago

CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...

GlobeNewsWire - 7 months ago

CORAL GABLES, Fla., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commerc...

GlobeNewsWire - 7 months ago

CORAL GABLES, Fla., July 31, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the Magistrate Judge considering Catalyst's lawsuit agains...

Zacks Investment Research - 7 months ago

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Newsfile Corp - 7 months ago

New York, New York--(Newsfile Corp. - July 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Catalyst Pharmaceuticals, Inc.

GuruFocus - 7 months ago

As the market continues to grapple with the effects of the coronavirus pandemic, some investors are seeing strength among U.S.

Other stocks mentioned: GRBK, HZO
GlobeNewsWire - 8 months ago

-Pete Curry has been Promoted to Vice President of Sales

Zacks Investment Research - 8 months ago

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 9 months ago

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.

About CPRX

Catalyst Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal musc... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2006
CEO
Patrick McEnany
Employees
76
Stock Exchange
NASDAQ
Ticker Symbol
CPRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is 7.40, which is an increase of 109.63% from the latest price.

Price Target
$7.40
(109.63% upside)
Analyst Consensus: Buy